A pilot study of adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients

Supportive Care in Cancer

Volumn 20, Issue 7, 2012, Pages 1565-1572

  Han, Hye Suk ^a   Shim, Young Kwang ^a   Kim, Jeong Eun ^a   Jeon, Hyun Jung ^a   Lim, Sung Nam ^a   Oh, Tae Keun ^a   Lee, Ki Hyeong ^a   Kim, Seung Taik ^a  

^a Chungbuk National University College of Medicine   (South Korea)

Author keywords

Adrenal suppression; Antiemetic; Cancer; Dexamethasone

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; MEGESTROL ACETATE; OXALIPLATIN; PLATINUM COMPLEX; PREDNISOLONE; SEROTONIN 3 ANTAGONIST;

ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ADULT; AGED; ANOREXIA; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLORECTAL CANCER; CORTICOTROPIN TEST; DRUG MEGADOSE; DRUG USE; FEMALE; HUMAN; INCIDENCE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; STEROID THERAPY; STOMACH CANCER; SYSTEMIC THERAPY; VISUAL ANALOG SCALE;

ADRENAL INSUFFICIENCY; ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MEGESTROL ACETATE; MIDDLE AGED; NAUSEA; NEOPLASMS; PILOT PROJECTS; PREDNISOLONE; PROSPECTIVE STUDIES; QUALITY OF LIFE; TIME FACTORS; VOMITING;

EID: 84863984239     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1248-z     Document Type: Article

References (28)

1. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MH (1996) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7: 189-195
2. Laszlo J, Lucas VS Jr (1981) Emesis as a critical problem in chemotherapy. N Engl J Med 305: 948-949
3. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95: 155-163
4. American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24: 2932-2947
5. Roila F, Tonato M, Basurto C, Picciafuoco M, Bracarda S, Donati D, Malacarne P, Monici L, Di Costanzo F, Patoia L et al (1989) Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J Clin Oncol 7: 1693-1700
6. Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C (1997) Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15: 2966-2973
7. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocol 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 21: 4112-4119
8. Arlt W, Allolio B (2003) Adrenal insufficiency. Lancet 361: 1881-1893
9. Oelkers W (1996) Adrenal insufficiency. N Engl J Med 335: 1206-1212
10. Seravalli L (2009) Predisposing factors for adrenal insufficiency. N Engl J Med 361: 824-825
11. Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J (2008) Harrison's principles of internal medicine, 17th edn. McGraw-Hill, New York, pp 2262-2266
12. Tordjman K, Jaffe A, Trostanetsky Y, Greenman Y, Limor R, Stern N (2000) Low-dose (1 microgram) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitaryadrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test. Clin Endocrinol 52: 633-640
13. Byyny RL (1976) Withdrawal from glucocorticoid therapy. N Engl J Med 295: 30-32
14. Myles AB, Schiller LF, Glass D, Daly JR (1976) Single daily dose corticosteroid treatment. Ann Rheum Dis 35: 73-76
15. Schlaghecke R, Kornely E, Santen RT, Ridderskamp P (1992) The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 326: 226-230
16. Christy NP (1992) Pituitary-adrenal function during corticosteroid therapy. Learning to live with uncertainty. N Engl J Med 326: 266-267
17. Spiegel RJ, Vigersky RA, Oliff AI, Echelberger CK, Bruton J, Poplack DG (1979) Adrenal suppression after short-term corticosteroid therapy. Lancet 1: 630-633
18. Carella MJ, Srivastava LS, Gossain VV, Rovner DR (1993) Hypothalamic-pituitary-adrenal function one week after a short burst of steroid therapy. J Clin Endocrinol Metab 76: 1188-1191
19. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA (2000) Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 355: 542-545
20. Schmoll E, Wilke H, Thole R, Preusser P, Wildfang I, Schmoll HJ (1991) Megestrol acetate in cancer cachexia. Semin Oncol 18: 32-34
21. Loprinzi CL (1995) Management of cancer anorexia/cachexia. Support Care Cancer 3: 120-122
22. Tchekmedyian NS, Hickman M, Siau J, Greco FA, Keller J, Browder H, Aisner J (1992) Megestrol acetate in cancer anorexia and weight loss. Cancer 69: 1268-1274
23. Naing KK, Dewar JA, Leese GP (1999) Megestrol acetate therapy and secondary adrenal suppression. Cancer 86: 1044-1049
24. Ron IG, Soyfer V, Goldray D, Inbar MJ, Weisman Y (2002) A low-dose adrenocorticotropin test reveals impaired adrenal function in cancer patients receiving megestrol acetate therapy. Eur J Cancer 38: 1490-1494
25. Orme LM, Bond JD, Humphrey MS, Zacharin MR, Downie PA, Jamsen KM, Mitchell SL, Robinson JM, Grapsas NA, Ashley DM (2003) Megestrol acetate in pediatric oncology patients may lead to severe, symptomatic adrenal suppression. Cancer 98: 397-405
26. Loprinzi CL, Jensen MD, Jiang NS, Schaid DJ (1992) Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clinic Proc 67: 1160-1162
27. Lamberts SW, Bruining HA, de Jong FH (1997) Corticosteroid therapy in severe illness. N Engl J Med 337: 1285-1292
28. Morrow GR, Hickok JT, Andrews PL, Stern RM (2002) Reduction in serum cortisol after platinum based chemotherapy for cancer: a role for the HPA axis in treatment-related nausea? Psychophysiology 39: 491-495